Cardiovascular

Latest News

FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication

September 16th 2023

Even though committee members voted in support of Onpattro for patients with cardiomyopathy related to transthyretin-mediated amyloidosis, there were questions about whether it provided a clinically meaningful benefit. The FDA set an action date of Oct. 8, 2023.

 FDA Approves First Anti-inflammatory Drug for Cardiovascular Disease
FDA Approves First Anti-inflammatory Drug for Cardiovascular Disease

June 20th 2023

New Heart Failure Drug Likely to be Cost-Effective in Hospitalized Patients
New Heart Failure Drug Likely to be Cost-Effective in Hospitalized Patients

June 6th 2023

  New Heart Failure Med Will be Priced 'Competitively'
New Heart Failure Med Will be Priced 'Competitively'

May 30th 2023

FDA Extends Evkeeza Indication to Include Young Children
FDA Extends Evkeeza Indication to Include Young Children

March 22nd 2023

More News

© 2023 MJH Life Sciences

All rights reserved.